Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma

Bharat Jasani, Sharon Coleman, Eric Butchart, Eve M L Evans, Malcolm Adams, Malcolm Mason, Allen Gibbs, Zsuzsanna Tabi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Diffuse malignant pleural mesothelioma (MPM) is the third most common lung malignancy showing rising incidence with 250,000 deaths expected from it in Western Europe over the next 35 year. The tumour is generally resistant to conventional treatment and there is urgent need for novel preventative and therapeutic measures to combat this growing public threat. Finding of SV40 DNA sequences in a high proportion (40-90%) of several series of MPM cases, and suggestion of its potential co-carcinogen role provide a rationale for the development of novel anti-MPM vaccines incorporating SV40 gene sequences or antigenic determinants. As a prelude to adopting this approach, general T cell function was examined in relatively early cases of MPM presenting for biopsy or debulking surgery. CD8+ T cell responses were studied using antigenic epitopes of common viral antigens covering a broad range of haplotypes. 74.1% (20/27) of MPM patients and 80% (8/10) of the control subjects showed T cell responsiveness to the viral peptides mix, whilst a small proportion showed SV40 specific recall immunity.

Original languageEnglish
Pages (from-to)2399-2402
Number of pages4
JournalVaccine
Volume23
Issue number17-18
DOIs
Publication statusPublished - Mar 18 2005
Externally publishedYes

Fingerprint

mesothelioma
Immunocompetence
Immunity
immunity
T-lymphocytes
T-Lymphocytes
epitopes
Epitopes
nucleotide sequences
Viral Antigens
viral antigens
carcinogens
Western European region
Carcinogens
Haplotypes
biopsy
Neoplasms
haplotypes
Vaccines
surgery

Keywords

  • Immunotherapy
  • Malignant pleural mesothelioma
  • T cell recall responses

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Jasani, B., Coleman, S., Butchart, E., Evans, E. M. L., Adams, M., Mason, M., ... Tabi, Z. (2005). Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. Vaccine, 23(17-18), 2399-2402. https://doi.org/10.1016/j.vaccine.2005.01.019

Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. / Jasani, Bharat; Coleman, Sharon; Butchart, Eric; Evans, Eve M L; Adams, Malcolm; Mason, Malcolm; Gibbs, Allen; Tabi, Zsuzsanna.

In: Vaccine, Vol. 23, No. 17-18, 18.03.2005, p. 2399-2402.

Research output: Contribution to journalArticle

Jasani, B, Coleman, S, Butchart, E, Evans, EML, Adams, M, Mason, M, Gibbs, A & Tabi, Z 2005, 'Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma', Vaccine, vol. 23, no. 17-18, pp. 2399-2402. https://doi.org/10.1016/j.vaccine.2005.01.019
Jasani, Bharat ; Coleman, Sharon ; Butchart, Eric ; Evans, Eve M L ; Adams, Malcolm ; Mason, Malcolm ; Gibbs, Allen ; Tabi, Zsuzsanna. / Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. In: Vaccine. 2005 ; Vol. 23, No. 17-18. pp. 2399-2402.
@article{7c454b0152144667b99f483bab6daf77,
title = "Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma",
abstract = "Diffuse malignant pleural mesothelioma (MPM) is the third most common lung malignancy showing rising incidence with 250,000 deaths expected from it in Western Europe over the next 35 year. The tumour is generally resistant to conventional treatment and there is urgent need for novel preventative and therapeutic measures to combat this growing public threat. Finding of SV40 DNA sequences in a high proportion (40-90{\%}) of several series of MPM cases, and suggestion of its potential co-carcinogen role provide a rationale for the development of novel anti-MPM vaccines incorporating SV40 gene sequences or antigenic determinants. As a prelude to adopting this approach, general T cell function was examined in relatively early cases of MPM presenting for biopsy or debulking surgery. CD8+ T cell responses were studied using antigenic epitopes of common viral antigens covering a broad range of haplotypes. 74.1{\%} (20/27) of MPM patients and 80{\%} (8/10) of the control subjects showed T cell responsiveness to the viral peptides mix, whilst a small proportion showed SV40 specific recall immunity.",
keywords = "Immunotherapy, Malignant pleural mesothelioma, T cell recall responses",
author = "Bharat Jasani and Sharon Coleman and Eric Butchart and Evans, {Eve M L} and Malcolm Adams and Malcolm Mason and Allen Gibbs and Zsuzsanna Tabi",
year = "2005",
month = "3",
day = "18",
doi = "10.1016/j.vaccine.2005.01.019",
language = "English",
volume = "23",
pages = "2399--2402",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "17-18",

}

TY - JOUR

T1 - Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma

AU - Jasani, Bharat

AU - Coleman, Sharon

AU - Butchart, Eric

AU - Evans, Eve M L

AU - Adams, Malcolm

AU - Mason, Malcolm

AU - Gibbs, Allen

AU - Tabi, Zsuzsanna

PY - 2005/3/18

Y1 - 2005/3/18

N2 - Diffuse malignant pleural mesothelioma (MPM) is the third most common lung malignancy showing rising incidence with 250,000 deaths expected from it in Western Europe over the next 35 year. The tumour is generally resistant to conventional treatment and there is urgent need for novel preventative and therapeutic measures to combat this growing public threat. Finding of SV40 DNA sequences in a high proportion (40-90%) of several series of MPM cases, and suggestion of its potential co-carcinogen role provide a rationale for the development of novel anti-MPM vaccines incorporating SV40 gene sequences or antigenic determinants. As a prelude to adopting this approach, general T cell function was examined in relatively early cases of MPM presenting for biopsy or debulking surgery. CD8+ T cell responses were studied using antigenic epitopes of common viral antigens covering a broad range of haplotypes. 74.1% (20/27) of MPM patients and 80% (8/10) of the control subjects showed T cell responsiveness to the viral peptides mix, whilst a small proportion showed SV40 specific recall immunity.

AB - Diffuse malignant pleural mesothelioma (MPM) is the third most common lung malignancy showing rising incidence with 250,000 deaths expected from it in Western Europe over the next 35 year. The tumour is generally resistant to conventional treatment and there is urgent need for novel preventative and therapeutic measures to combat this growing public threat. Finding of SV40 DNA sequences in a high proportion (40-90%) of several series of MPM cases, and suggestion of its potential co-carcinogen role provide a rationale for the development of novel anti-MPM vaccines incorporating SV40 gene sequences or antigenic determinants. As a prelude to adopting this approach, general T cell function was examined in relatively early cases of MPM presenting for biopsy or debulking surgery. CD8+ T cell responses were studied using antigenic epitopes of common viral antigens covering a broad range of haplotypes. 74.1% (20/27) of MPM patients and 80% (8/10) of the control subjects showed T cell responsiveness to the viral peptides mix, whilst a small proportion showed SV40 specific recall immunity.

KW - Immunotherapy

KW - Malignant pleural mesothelioma

KW - T cell recall responses

UR - http://www.scopus.com/inward/record.url?scp=14844297682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844297682&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.01.019

DO - 10.1016/j.vaccine.2005.01.019

M3 - Article

VL - 23

SP - 2399

EP - 2402

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-18

ER -